

### The Role of Pulsed High Intensity Focused Ultrasound (pHIFU) in Cancer Therapy

Fox Chase Cancer Center



Lili Chen, PhD Department of Radiation Oncology



### **Background of the Studies**

 Exablate 2000 HIFU system installed in the Dept of Rad Onc at FCCC in 2006





T FOX CHASE



T2-weighted MRI (1.5T) Resolution: 0.23 mm

FOX CHASE

### Motivation

### <u>Hypothesis</u>

pHIFU exposures enhances drug delivery and increases the efficacy of gene/chemotherapy in inhibiting prostate cancer growth *in vivo*, particularly when combined with AD (androgen deprivation) or RT.

### Purpose of the study

To verify the concept of enhancing drug uptake with MR guided pHIFU.

FOX CHASE





Charlie Ma, Lili Chen, Alan Pollack, Dusica Cvetkovic, Zhaomei Mu, Xiaoming Chen, Bin Wang, Roohi Gupta

## Pilot Study (1) Doxorubicin



Figure 4 Companion of the doxenubicin concentration in tumors with and which HIPU relationes in 0.02 with HIPU and 0.025 without HIPU restriment.

Parameters: 1 MHz; 4 W of acoustic power and 5 Hz frequency with 50% duty cycle (0.1s power on, 0.1s power off) for 1 minute /per sonication

**FOX CHASE** CANCER CENTER



### Pilot study (2) Cellular uptake of AS-MDM2 with MRgHIFU in vivo

- MDM2 is an oncogene and overexpressed in 30-40% of prostate cancer. Antisense MDM2 oligonucleotide (AS-MDM2) inhibits MDM2 expression, and enhances the effects of radiation and chemotherapy on prostate cancer
- The purpose of this study is to investigate the feasibility of increasing the cellular uptake of AS-MDM2 using MR guided Pulsused High Intensity Focused Ultrasound (pHIFU).

FOX CHASE



T FOX CHASE

# <image>

Figure 6 Thg percentage of cells showing MDM2, p53 and P21 expression after immunohistochemical staining with MDM2 (1:400 concentration), P53 (1:500 concentration) and P21 (1:4000 concentration).

T FOX CHASE



### Intratumoral uptake of [<sup>3</sup>H]docetaxel in vivo using MRgHIFU

- The purpose of the study
  - if the delivery of <sup>3</sup>H-docetaxel is enhanced in the treated prostate tumor then the insignificant results from the gene therapy experiments would be due to the ineffectiveness of the gene drug
- The rational of selection of Docetaxel
- 1. Routinely used in clinic
- 2. A potent radio-sensitizer: used for quantitative measurement T FOX CHASE



### Study Design

- LNCaP 10<sup>6</sup>, were grown orthotopically in the prostates of mice
- Three groups: 1) pHIFU+ <sup>3</sup>H-docetaxel, 2) <sup>3</sup>Hdocetaxel alone, 3) control
- Use the same treatment pHIFU parameters as for gene therapy
- <sup>3</sup>H-docetaxel (1.25 µci/25 g) received by tail vein immediately after pHIFU.
- Animals euthanized 30 minutes post treatment and the <sup>3</sup>H-docetaxel were measured quantitatively (cmp counts) using a scintillation detector

FOX CHASE

### Animal Setup and Focal Spot Calibration





### **Treatment Planning in Real Time**



### **Real Time Monitoring**





Fig. 3. Real-time temperature measurement with MR thermometry during animal sociection (top red line: maximum temperature measured at the focalspot in a single yoard of 0.86 × 1.72 × 3.00 mm; bottom gmeen line: average temperature measured over 3 yoards). The ambient temperature was ac du 35 °C, which was the typical mouse body temperature in the beginning of the sonication period.

### **Results**

- No skin damage
- No death of animals during or after the pHIFU treatment



Immediately after pHIFU

FOX CHASE

### Comparison of <sup>3</sup>H-docetaxel in Tumor with and without pHIFU





Quantitative study of Enhancement of Doxorubicin Delivery in Prostate Cancer *in vivo* with MRgHIFU

### • "Optimal" treatment parameters

- 1 MHz, 25 W acoustic power, and 1 Hz pulse rate with a 10% duty cycle for 60 s for each spot.

### Temperature elevations

<5 °C observed during the treatment,

Chen X et al. Med. Phys. 39 (5), (2012)2780-86

T FOX CHASE





### Results

Comparison of Dox with and without pHIFU









 

 Dox Distribution in Prostate Tumor after pHIFU

 control
 Dox

 pHIFU + Dox

X 20

### FOX CHASE



### Evaluation of the Efficacy of the Enhancement of Docetaxel by pHIFU for Prostate Treatment

- 1) Docetaxel + pHIFU in tumor growth control
- 2) Docetaxel +pHIFU +RT in tumor growth control
- 3) pHIFU + RT using "optimal" pHIFU parameters and tumor sizes
- 4) pHIFU alone for tumor growth control

T FOX CHASE



### Study (1) - Study Design

- Tumor volume:  $45 \pm 9 \text{ mm}^3$  measured on MRI
- 4 Groups (n=5) (1)pHIFU alone
  - (2)docetaxel + pHIFU
  - (3) docetaxel alone
  - (4)Control

T FOX CHASE



### Study (1) - Study design (continued)

Groups 1 and 2 = pHIFU/week x 2 Groups 2 and 3 = docetaxel by i.v. 10 mg/ kg/week x 2 Group 2 i.v injection immediately after pHIFU

•pHIFU parameters: 1MHz; 5W, 50% duty cycle (0.1 s power on and 0.1 s power off) for 60 s per sonication

•Tumor volume measured on MR (1.5T) weekly for 4 weeks

T FOX CHASE



### Study (2)

- Redused docetaxel dose from 10 mg/kg to 5 mg/kg for one injection) pHIFU treatment also for one time TX with the same
- parameters





### Study (3)

Purpose: Evaluation of the Therapeutic Effects of pHIFU + RT  $\ensuremath{\mathsf{PI}}$ 

- 1. Using "optimal" pHIFU treatment parameters
- 2. RT dose: 2 Gy (Siemens Artiste linear accelerator )

### **FOX CHASE** CANCER CENTER





pHIFU parameters:1MHz; 5W for 60 s with 50% duty cycle (0.1 s power on and 0.1 s power off) per sonication

### Study (4) Therapeutic Effect of pHIFU Alone





### Therapeutic Effect of pHIFU on Tumor Growth



Ma et al. Med. Phys. 41 (2014) 122901-1-9

### ImmunoChemical Staining-Caspase to detect apoptotic cells 24 h after treatment



The apoptosis induced by pHIFU is comparable to that by 2 Gy irradiation

Ma et al. Med. Phys. 41 (2014) 122901-1-9

### ImmunoChemical StainingyH2AX and Chk2 indicating DNA damage

48 h after treatment, the two biomarkers are in creased in the HIFU treated mice compared with the control group.

Ma et al. Med. Phys. 41 (2014) 122901-1-9



### **Conclusions/discussions**

Animal studies demonstrated the effectiveness of enhancement of chemotherapy by pHIFU in combination with RT for prostate tumor control *in vivo* 

The therapeutic effect of pHIFU alone may be clinically significant.

FOX CHASE

12



### **Conclusions/discussions**

- There appeared to be an earlier treatment response to pHIFU than to RT, indicating different cell killing mechanisms between the two modalities.
- There was a tendency toward accelerated tumor growth in pHIFU treated tumors compared to the control mice.
- The therapeutic effect of pHIFU may be a combined result from mitotic, apoptotic, and necrotic cell death due to biophysical and biochemical reactions mediated by pHIFU with different components of the tumor cell including DNA, cell membrane, mitochondria, etc.

### **Future Work**

Further experiments are warranted to understand the cell killing mechanisms of pHIFU and to derive optimal ultrasound parameters and fractionation schemes to maximize the therapeutic effect of pHIFU.

### **FOX CHASE** CANCER CENTER



### Acknowledgements

Focused Ultrasound Surgery Foundation

>DOD PC073127

>DOD BC102806

NIH P30 CA 00-6927

InSightec Inc for technical support

Core research facilities at Fox Chase Cancer Center for technical support

T FOX CHASE